According to a recent study published in JAMA Dermatology, which of the following factors do NOT contribute to treatment delay in melanoma?

Conferences

Researchers at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, have identified a potential biomarker in patients with stage IV melanoma being treated with the immunotherapy pembrolizumab.

Read More

News

An adjuvant combination regimen may improve the rate of relapse-free survival by 19% in patients with stage III BRAF-mutated melanoma, according to a recent study in the New England Journal of Medicine (online September 10, 2017; doi:10.1056/NEJMoa1708539).

Read More

Recently published long-term survival data shows the benefits of combining two conventional therapies to treat patients with advanced melanoma.

Read More

By Ben Hirschler

MADRID (Reuters) - Bristol-Myers Squibb’s immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients who have had surgery to remove disease, researchers reported on Monday.

Read More

By Marilynn Larkin

NEW YORK (Reuters Health) – People who carry a BsmI single-nucleotide polymorphism (SNP) are twice as likely to develop nonmelanoma skin cancer (NMSC) as their peers with similar known risk factors, such as older age, male sex, and light eye and skin color, researchers say.

Read More

Quiz

According to a recent study published in JAMA Dermatology, which of the following factors do NOT contribute to treatment delay in melanoma?

Research in Review

Central nervous system imaging is needed during programmed death 1 (PD-1) inhibitor therapy to monitor incidence, patterns of progression, and outcomes of melanoma brain metastases, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Financial toxicity and excessive financial burden appeared common among melanoma survivors, frequently leading to disease-related distress, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Stage III and IV melanoma may have a profound impact on patients’ distress burden, which requires further intervention strategies, according to research that will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

The treatment of advanced melanoma represents a significant burden to the health system, and differs by insurance type and geographic location, according to the results of a regional analysis.

-----

Related Content

Read More

Resources

The National Comprehensive Cancer Network released updated guidelines for the treatment of basal cell skin cancer, squamous cell skin cancer, and merkel cell carcinoma.
Subscribe to Skin Cancer